Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

fludarabine 5Cyclophosphamide 5aldesleukin 4Radiotherapy 4fludarabine phosphate 2entinostat 2aflibercept 2Trastuzumab 2Adoptive Transfer 2trastuzumab deruxtecan 1tipifarnib 1rocakinogene sifuplasmid 1durvalumab 1bintrafusp alfa protein, human 1Vinorelbine 1VGX-3100 1Ritonavir 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Octreotide 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1MEDI0457 1Interleukin-2 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaginal Neoplasms × MEDI0457 × Genitourinary × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡